Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback

October 6, 2016 6:44 AM EDT
Get Alerts MDCO Hot Sheet
Price: $32.82 -1.65%

Rating Summary:
    15 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade MDCO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst Biren Amin reiterated his Buy rating and $43 price target on The Medicines Company (NASDAQ: MDCO) saying Alnylam Pharmaceuticals (NASDAQ: ALNY) set back has no read-through to the company's PCSK9 Program.

Amin commented, "ALNY announced that revusiran was stopped due to lack of a treatment benefit w/ an imbalance of deaths favoring the revusiran arm over placebo. The imbalance was not tx-related. As a result of ALNY's update, MDCO provided a safety update on ALN-PCSsc in which it reported no imbalances to date on peripheral neuropathy, liver toxicity, renal toxicity, and mortality from its 501-patient ORION-1 study. Data from this trial are expected at AHA on Nov 15."

MDCO last traded down 10.4% in pre-open trade to $34.50.

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA, Hot Comments, Trader Talk

Related Entities

Jefferies & Co, Pre Market Movers

Add Your Comment